ES533668A0
(es)
*
|
1983-06-24 |
1985-10-01 |
Yamanouchi Pharma Co Ltd |
Un compuesto fenoxi
|
CN1003445B
(zh)
*
|
1984-10-03 |
1989-03-01 |
武田药品工业株式会社 |
噻唑烷二酮衍生物,其制备方法和用途
|
US4812570A
(en)
*
|
1986-07-24 |
1989-03-14 |
Takeda Chemical Industries, Ltd. |
Method for producing thiazolidinedione derivatives
|
FI91869C
(fi)
*
|
1987-03-18 |
1994-08-25 |
Tanabe Seiyaku Co |
Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
|
US4968707A
(en)
*
|
1987-06-10 |
1990-11-06 |
Pfizer Inc. |
Oxazolidin-2-one derivatives as hypoglycemic agents
|
EP0295828A1
(en)
*
|
1987-06-13 |
1988-12-21 |
Beecham Group Plc |
Novel compounds
|
GB8713861D0
(en)
*
|
1987-06-13 |
1987-07-15 |
Beecham Group Plc |
Compounds
|
US4791125A
(en)
*
|
1987-12-02 |
1988-12-13 |
Pfizer Inc. |
Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
|
US4798835A
(en)
*
|
1987-12-02 |
1989-01-17 |
Pfizer Inc. |
dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
|
GB8820389D0
(en)
*
|
1988-08-26 |
1988-09-28 |
Beecham Group Plc |
Novel compounds
|
GB8919417D0
(en)
|
1989-08-25 |
1989-10-11 |
Beecham Group Plc |
Novel compounds
|
US4997948A
(en)
*
|
1989-10-27 |
1991-03-05 |
American Home Products |
5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
|
US5356913A
(en)
*
|
1990-02-09 |
1994-10-18 |
The Upjohn Company |
Use of insulin sensitizing agents to treat hypertension
|
KR0170416B1
(ko)
†
|
1990-02-09 |
1999-02-18 |
로버트 에이. 아미테이지 |
고혈압 치료를 위한 인슐린 증감제의 용도
|
ATE205206T1
(de)
*
|
1990-04-27 |
2001-09-15 |
Sankyo Co |
Benzylidenthiazolidinderivate, ihre herstellung und ihre anwendung als lipidperoxid-inhibitoren
|
GB9023584D0
(en)
*
|
1990-10-30 |
1990-12-12 |
Beecham Group Plc |
Novel compounds
|
US5158966A
(en)
*
|
1991-02-22 |
1992-10-27 |
The University Of Colorado Foundation, Inc. |
Method of treating type i diabetes
|
AU1743292A
(en)
*
|
1991-04-11 |
1992-11-17 |
Takeda Chemical Industries Ltd. |
Thiazolidinedione derivatives, production and use thereof
|
US5183823A
(en)
*
|
1991-04-11 |
1993-02-02 |
Takeda Chemical Industries, Ltd. |
Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
|
US5441971A
(en)
*
|
1991-04-11 |
1995-08-15 |
The Upjohn Company |
Thiazolidinedione derivatives, production and use thereof
|
FR2680512B1
(fr)
*
|
1991-08-20 |
1995-01-20 |
Adir |
Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
|
GB9124513D0
(en)
*
|
1991-11-19 |
1992-01-08 |
Smithkline Beecham Plc |
Novel process
|
GB9218830D0
(en)
*
|
1992-09-05 |
1992-10-21 |
Smithkline Beecham Plc |
Novel compounds
|
US5741803A
(en)
*
|
1992-09-05 |
1998-04-21 |
Smithkline Beecham Plc |
Substituted thiazolidinedionle derivatives
|
NZ248573A
(en)
*
|
1992-09-10 |
1996-02-27 |
Lilly Co Eli |
5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions
|
US5594016A
(en)
*
|
1992-12-28 |
1997-01-14 |
Mitsubishi Chemical Corporation |
Naphthalene derivatives
|
JP2845743B2
(ja)
*
|
1992-12-28 |
1999-01-13 |
三菱化学株式会社 |
新規なナフタレン誘導体
|
USRE39384E1
(en)
|
1993-09-01 |
2006-11-07 |
Smithkline Beecham P.L.C. |
Substituted thiazolidinedione derivatives
|
ATE376829T1
(de)
*
|
1993-09-15 |
2007-11-15 |
Daiichi Sankyo Co Ltd |
Verwendung von thiazolidindionen zur vorbeugung oder verzögerung des auftretens des nichtinsulinabhängigen diabetes mellitus (niddm)
|
US6046222A
(en)
*
|
1993-09-15 |
2000-04-04 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
US5874454A
(en)
*
|
1993-09-15 |
1999-02-23 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
US5457109A
(en)
*
|
1993-09-15 |
1995-10-10 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
DK0749430T3
(da)
*
|
1994-03-08 |
2000-02-07 |
American Home Prod |
Thiazolidindion-derivater som antihyperglykæmiske midler
|
US6251928B1
(en)
*
|
1994-03-16 |
2001-06-26 |
Eli Lilly And Company |
Treatment of alzheimer's disease employing inhibitors of cathepsin D
|
DE69530501D1
(de)
*
|
1994-10-20 |
2003-05-28 |
Nippon Chemiphar Co |
Chinolinderivat
|
US5708012A
(en)
*
|
1995-04-28 |
1998-01-13 |
Sankyo Company, Limited |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
|
AU5121796A
(en)
*
|
1995-05-08 |
1996-11-29 |
Nippon Chemiphar Co. Ltd. |
2,4-thiazolidinedione or oxazolidinedione derivatives and hy poglycemic agent
|
TW438587B
(en)
|
1995-06-20 |
2001-06-07 |
Takeda Chemical Industries Ltd |
A pharmaceutical composition for prophylaxis and treatment of diabetes
|
HUP9601808A3
(en)
*
|
1995-07-03 |
2000-06-28 |
Sankyo Co |
Treatment of arteriosclerosis and xanthoma
|
EP0783888A1
(en)
|
1995-12-26 |
1997-07-16 |
Sankyo Company Limited |
Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
|
IL120443A
(en)
*
|
1996-03-18 |
2000-07-16 |
Sankyo Co |
Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
|
US5958957A
(en)
*
|
1996-04-19 |
1999-09-28 |
Novo Nordisk A/S |
Modulators of molecules with phosphotyrosine recognition units
|
JP2000511883A
(ja)
*
|
1996-04-19 |
2000-09-12 |
ノボ ノルディスク アクティーゼルスカブ |
ホスホチロシン認識ユニットを有する分子のモジュレーター
|
CA2257284C
(en)
*
|
1996-05-31 |
2005-10-04 |
Sankyo Company Limited |
Remedy for autoimmune diseases
|
US5952509A
(en)
*
|
1996-06-27 |
1999-09-14 |
Takeda Chemical Industries, Ltd. |
Production of benzaldehyde compounds
|
WO1998020871A1
(fr)
*
|
1996-11-08 |
1998-05-22 |
Nippon Chemiphar Co., Ltd. |
Agent diminuant la graisse viscerale
|
DE69838789T2
(de)
*
|
1997-03-12 |
2008-10-30 |
Suzanne Cambridge de la Monte |
Verfahren zur behandlung oder prävention der alzheimerischen krankheit
|
US5908859A
(en)
*
|
1997-08-11 |
1999-06-01 |
Eli Lilly And Company |
Benzothiophenes for inhibiting hyperlipidemia
|
HUP9902721A2
(hu)
|
1997-11-25 |
1999-12-28 |
The Procter & Gamble Co. |
Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
|
GB9726568D0
(en)
*
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
WO1999030739A1
(fr)
*
|
1997-12-16 |
1999-06-24 |
Sankyo Company, Limited |
Remede contre la leucemie
|
US20040058873A1
(en)
*
|
1998-03-12 |
2004-03-25 |
Esmond Robert W. |
Method for treating or preventing Alzheimer's disease
|
EP1143953A3
(en)
*
|
1998-11-20 |
2002-02-06 |
Genentech, Inc. |
Method of inhibiting angiogenesis
|
US6191154B1
(en)
|
1998-11-27 |
2001-02-20 |
Case Western Reserve University |
Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
|
TWI249401B
(en)
*
|
1999-04-14 |
2006-02-21 |
Takeda Chemical Industries Ltd |
Agent for improving ketosis
|
JP4693247B2
(ja)
|
1999-04-28 |
2011-06-01 |
有限会社ケムフィズ |
複素環カルボン酸誘導体
|
EP1109796A1
(en)
*
|
1999-07-01 |
2001-06-27 |
Geron Corporation |
Telomerase inhibitors and methods of their use
|
JP2001072592A
(ja)
|
1999-07-01 |
2001-03-21 |
Kyowa Hakko Kogyo Co Ltd |
テロメラーゼ阻害剤
|
US7390824B1
(en)
*
|
1999-09-07 |
2008-06-24 |
Bristol-Myers Squibb Company |
Method for treating diabetes employing an aP2 inhibitor and combination
|
US6559188B1
(en)
|
1999-09-17 |
2003-05-06 |
Novartis Ag |
Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
|
US6878749B2
(en)
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
AR028299A1
(es)
|
1999-09-17 |
2003-05-07 |
Novartis Ag |
Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
|
ES2156574B1
(es)
|
1999-11-18 |
2002-02-01 |
Vita Invest Sa |
Nuevos derivados de tiazolidindiona como agentes antidiabeticos
|
US6589963B2
(en)
|
1999-12-03 |
2003-07-08 |
Kyoto Pharmaceutical Industries, Ltd. |
Heterocyclic compounds and salts thereof and medicinal use of the same
|
DK1741447T3
(da)
|
2000-01-21 |
2013-12-09 |
Novartis Ag |
Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
|
US6958355B2
(en)
*
|
2000-04-24 |
2005-10-25 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
US6680387B2
(en)
*
|
2000-04-24 |
2004-01-20 |
Aryx Therapeutics |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
US6770133B2
(en)
*
|
2000-04-25 |
2004-08-03 |
Kyorin Pharmaceutical Co., Ltd. |
Stable crystal of thiazolidinedione derivative and process for producing the same
|
AU2001294673A1
(en)
*
|
2000-09-21 |
2002-04-02 |
Aryx Therapeutics |
Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
US6452014B1
(en)
|
2000-12-22 |
2002-09-17 |
Geron Corporation |
Telomerase inhibitors and methods of their use
|
EP1695716A2
(en)
*
|
2000-12-26 |
2006-08-30 |
Sankyo Company, Limited |
Medicinal compositions containing diuretics and insulin sensitizers
|
CZ309209B6
(cs)
*
|
2001-01-26 |
2022-05-25 |
Schering Corporation |
Farmaceutický prostředek
|
SI1353694T1
(sl)
*
|
2001-01-26 |
2008-06-30 |
Schering Corp |
Kombinacije ezetimiba z aspirinom za zdravljenejevaskularnih stanj
|
EP1671650A1
(en)
*
|
2001-01-26 |
2006-06-21 |
Schering Corporation |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
|
DE60221798T2
(de)
*
|
2001-01-26 |
2008-06-05 |
Schering Corp. |
Kombinationen von gallensäure sequestriermitteln und hemmern der sterol absorption zur behandlung von kardiovaskulären indikationen
|
CA2434436A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Teddy Kosoglou |
Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
|
ME00145B
(me)
*
|
2001-01-26 |
2010-10-10 |
Merck Sharp & Dohme |
Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
ES2282386T3
(es)
*
|
2001-02-24 |
2007-10-16 |
BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG |
Derivados de xantina, su preparacion y su uso como medicamentos.
|
KR200249057Y1
(ko)
*
|
2001-03-22 |
2001-10-19 |
김진환 |
뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
|
EP1381361B1
(en)
*
|
2001-04-04 |
2009-02-25 |
Ortho-McNeil-Janssen Pharmaceuticals, Inc. |
Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
|
US20060047000A1
(en)
*
|
2001-04-24 |
2006-03-02 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
DE60237594D1
(de)
*
|
2001-04-25 |
2010-10-21 |
Takeda Pharmaceutical |
Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans
|
PL363738A1
(en)
|
2001-04-26 |
2004-11-29 |
Leciva A.S. |
Method for obtaining pioglitazone as an antidiabetic agent
|
KR20040030647A
(ko)
*
|
2001-05-29 |
2004-04-09 |
교토 야쿠힝 고교 가부시키가이샤 |
신규 복소환 화합물 및 그 의약 용도
|
PL367676A1
(en)
*
|
2001-05-29 |
2005-03-07 |
Kyoto Pharmaceutical Industries, Ltd. |
Novel heterocyclic derivatives and medicinal use thereof
|
WO2003013609A1
(en)
*
|
2001-08-03 |
2003-02-20 |
Takeda Chemical Industries, Ltd. |
Sustained-release medicines
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
DE60216300T2
(de)
*
|
2001-09-21 |
2007-06-28 |
Schering Corp. |
Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
SI1427409T1
(sl)
*
|
2001-09-21 |
2009-02-28 |
Schering Corp |
Postopki za zdravljenje ali preprečevanje vaskularnega vnetja z uporabo zaviralca(-ev) absorpcije sterola
|
AU2002337749A1
(en)
*
|
2001-09-28 |
2003-04-07 |
Teva Pharmaceutical Industries Ltd. |
Pioglitazone hydrochloride
|
US20050101638A1
(en)
*
|
2002-11-08 |
2005-05-12 |
Webb Randy L. |
Combination of organic compounds
|
US20050187258A1
(en)
*
|
2001-12-20 |
2005-08-25 |
Ben-Zion Dolitzky |
Hydrogenation of precursors to thiazolidinedione antihyperglycemics
|
US6992191B2
(en)
*
|
2001-12-20 |
2006-01-31 |
Teva Pharmaceutical Industries, Ltd. |
Hydrogenation of precursors to thiazolidinedione antihyperglycemics
|
ITRM20020016A1
(it)
*
|
2002-01-15 |
2003-07-15 |
Sigma Tau Ind Farmaceuti |
Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
|
WO2003062427A1
(fr)
*
|
2002-01-23 |
2003-07-31 |
Yamanouchi Pharmaceutical Co., Ltd. |
Methode de criblage de medicaments ameliorant la resistance a l'insuline
|
US7015345B2
(en)
*
|
2002-02-21 |
2006-03-21 |
Asahi Kasei Pharma Corporation |
Propionic acid derivatives
|
KR100450700B1
(ko)
*
|
2002-03-22 |
2004-10-01 |
주식회사종근당 |
티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
|
US20050119314A1
(en)
*
|
2002-04-05 |
2005-06-02 |
Sankyo Company, Limited |
Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
|
PL376577A1
(pl)
|
2002-06-17 |
2006-01-09 |
Themis Laboratories Private Limited |
Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
|
DE60316152D1
(de)
|
2002-07-16 |
2007-10-18 |
Cadila Healthcare Ltd |
Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen
|
US8993773B2
(en)
|
2002-07-16 |
2015-03-31 |
Cadila Healthcare Limited |
Process to prepare pioglitazone via several novel intermediates
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
AU2003260813A1
(en)
*
|
2002-09-12 |
2004-04-30 |
Themis Laboratories Private Limited |
Improved process for preparation of thiazolidinedione derivatives
|
WO2004026241A2
(en)
|
2002-09-20 |
2004-04-01 |
Andrx Labs Llc |
Multistage formulation containing a biguanide and thiazolidindione derivatives
|
US7785627B2
(en)
*
|
2002-09-20 |
2010-08-31 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US8084058B2
(en)
|
2002-09-20 |
2011-12-27 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US9060941B2
(en)
*
|
2002-09-20 |
2015-06-23 |
Actavis, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US7959946B2
(en)
|
2002-09-20 |
2011-06-14 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
CA2504878A1
(en)
*
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorption inhibitors for the treatment of demyelination
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
US7208486B2
(en)
|
2003-03-07 |
2007-04-24 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
MXPA05009503A
(es)
|
2003-03-07 |
2005-10-18 |
Schering Corp |
Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
WO2004081004A1
(en)
|
2003-03-07 |
2004-09-23 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
CA2518465A1
(en)
|
2003-03-25 |
2004-10-14 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
WO2004108721A1
(en)
*
|
2003-04-01 |
2004-12-16 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl] methyl]-2,4-thiazolidinedione
|
ES2219180B1
(es)
*
|
2003-05-09 |
2006-03-01 |
Medichem, S.A. |
Compuesto intermedio util para la preparacion de pioglitazona.
|
JP2007502847A
(ja)
*
|
2003-05-13 |
2007-02-15 |
シントン・ベスローテン・フェンノートシャップ |
チアゾリジンジオン誘導体およびその化合物を製造する方法
|
US7230016B2
(en)
|
2003-05-13 |
2007-06-12 |
Synthon Ip Inc. |
Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
|
SI1622899T1
(sl)
*
|
2003-05-13 |
2007-10-31 |
Synthon Bv |
Pioglitazonsulfat, farmacevtski sestavki in njihova uporaba
|
US20050004179A1
(en)
*
|
2003-05-22 |
2005-01-06 |
Pedersen Ward A. |
Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
|
JPWO2004106542A1
(ja)
*
|
2003-05-29 |
2006-07-20 |
三共株式会社 |
インスリン抵抗性改善剤及びそのスクリーニング方法
|
MXPA05012900A
(es)
|
2003-05-30 |
2006-02-22 |
Ranbaxy Lab Ltd |
Derivados de pirrol sustituidos.
|
US7723344B2
(en)
|
2003-08-13 |
2010-05-25 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
WO2005021542A2
(en)
*
|
2003-08-28 |
2005-03-10 |
Ranbaxy Laboratories Limited |
Process for the preparation of pioglitazone
|
WO2005021543A1
(en)
*
|
2003-09-03 |
2005-03-10 |
Biocon Limited |
Phosphoric acid salt of 5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2, 4-thiazolidinedione
|
EP1699777B1
(en)
|
2003-09-08 |
2012-12-12 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
WO2005027967A1
(ja)
*
|
2003-09-17 |
2005-03-31 |
Kaname Kawasugi |
医薬組成物
|
EP1680189A2
(en)
*
|
2003-11-05 |
2006-07-19 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
US7501426B2
(en)
*
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
EP1716144A2
(en)
*
|
2004-02-20 |
2006-11-02 |
Synthon B.V. |
Processes for making pioglitazone and compounds of the processes
|
GEP20094679B
(en)
|
2004-03-15 |
2009-05-10 |
Takeda Pharmaceuticals Co |
Dipeptidyl peptidase inhibitors
|
BRPI0509305A
(pt)
*
|
2004-03-29 |
2007-09-04 |
Sankyo Co |
uso de um sensibilizador insulìnico, composição farmecêutica, e , kit
|
US7161756B2
(en)
*
|
2004-05-10 |
2007-01-09 |
Tandberg Data Storage Asa |
Method and system for communication between a tape drive and an external device
|
US20060025478A1
(en)
*
|
2004-07-27 |
2006-02-02 |
Keisuke Inoue |
Medicine for prevention or treatment of diabetes
|
TW200608967A
(en)
*
|
2004-07-29 |
2006-03-16 |
Sankyo Co |
Pharmaceutical compositions containing with diabetic agent
|
WO2006022428A1
(ja)
*
|
2004-08-26 |
2006-03-02 |
Takeda Pharmaceutical Company Limited |
糖尿病治療剤
|
WO2006035459A1
(en)
*
|
2004-09-28 |
2006-04-06 |
Morepen Laboratories Limited |
An improved process for the production of derivatives of thiozolidinediones and their precursors
|
US20060089387A1
(en)
*
|
2004-10-26 |
2006-04-27 |
Le Huang |
Stabilized pharmaceutical composition comprising antidiabetic agent
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
US7833513B2
(en)
|
2004-12-03 |
2010-11-16 |
Rhode Island Hospital |
Treatment of Alzheimer's Disease
|
EP2805953B1
(en)
|
2004-12-21 |
2016-03-09 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
EA015382B1
(ru)
*
|
2005-03-08 |
2011-08-30 |
Никомед Гмбх |
Применение рофлумиласта для лечения сахарного диабета типа 2
|
US20070269486A1
(en)
*
|
2005-03-14 |
2007-11-22 |
Conor Medsystems, Llc. |
Methods and Devices for Reducing Tissue Damage After Ischemic Injury
|
JP2008533122A
(ja)
*
|
2005-03-18 |
2008-08-21 |
オーキッド ケミカルズ アンド ファーマシューティカルズ リミテッド |
新規なチロシン誘導体
|
WO2006117654A1
(en)
*
|
2005-05-03 |
2006-11-09 |
Ranbaxy Laboratories Limited |
Processes for the preparation of pioglitazone or salts thereof
|
JPWO2007007757A1
(ja)
*
|
2005-07-12 |
2009-01-29 |
第一三共株式会社 |
PPARγアゴニストを含有する医薬組成物
|
WO2007029062A2
(en)
*
|
2005-07-29 |
2007-03-15 |
Orchid Research Laboratories Limited |
Novel pyridine derivatives
|
DE102005035891A1
(de)
*
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
GEP20135838B
(en)
*
|
2005-09-14 |
2013-06-10 |
Takeda Pharmaceutical |
Dipeptidyl peptidase inhibitors usage at diabetes treatment
|
CA2622642C
(en)
|
2005-09-16 |
2013-12-31 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
JP2009514851A
(ja)
|
2005-11-08 |
2009-04-09 |
ランバクシー ラボラトリーズ リミテッド |
(3r,5r)−7−[2−(4−フルオロフェニル)−5−イソプロピル−3−フェニル−4−[(4−ヒドロキシメチルフェニルアミノ)カルボニル]−ピロール−1−イル]−3,5−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
|
TW200730173A
(en)
*
|
2005-12-16 |
2007-08-16 |
Sankyo Co |
Pharmaceutical composition enhancing production of adiponectin
|
ES2388555T3
(es)
*
|
2006-03-16 |
2012-10-16 |
Metabolic Solutions Development Company Llc |
Análogos de tiazolidindiona
|
ES2654908T3
(es)
|
2006-03-16 |
2018-02-15 |
Metabolic Solutions Development Company Llc |
Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica
|
CA2646170A1
(en)
*
|
2006-03-16 |
2007-09-27 |
Metabolic Solutions Development Company |
Combination therapies of thiazolidinedione analogues and glucocorticoid agonists
|
EP1852108A1
(en)
*
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
CN103951667A
(zh)
|
2006-05-04 |
2014-07-30 |
勃林格殷格翰国际有限公司 |
多晶型
|
PE20080251A1
(es)
*
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
CA2787343C
(en)
|
2006-06-26 |
2016-08-02 |
Amgen Inc. |
Compositions comprising modified lcat and uses thereof
|
KR100791399B1
(ko)
|
2006-09-06 |
2008-01-07 |
동우신테크 주식회사 |
염산 피오글리타존의 제조방법
|
EA200900392A1
(ru)
|
2006-09-07 |
2010-06-30 |
Никомед Гмбх |
Комбинированное лечение сахарного диабета
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
US20080182880A1
(en)
*
|
2006-09-28 |
2008-07-31 |
Mailatur Sivaraman Mohan |
Pioglitazone composition
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
CA2670730A1
(en)
*
|
2006-12-13 |
2008-06-26 |
Gilead Sciences, Inc. |
Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction
|
WO2008075380A2
(en)
*
|
2006-12-21 |
2008-06-26 |
Ind-Swift Laboratories Limited |
Process for the preparation of thiazolidine derivatives
|
US20080176905A1
(en)
*
|
2007-01-22 |
2008-07-24 |
Santiago Ini |
Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
|
CL2008000279A1
(es)
*
|
2007-02-01 |
2008-08-18 |
Takeda Pharmaceutical |
Composicion farmaceutica solida que comprende una parte que comprende 2-((6-(3r)-3-amino-1-piperidinil)3,4-dihidro-3-metil-2,4-dioxo-1-(2h)-pirimidin)metil)benzonitrilo, azucar o alcohol de azucar y una segunda parte que comprende pioglitazona y azuc
|
KR101126383B1
(ko)
|
2007-02-07 |
2012-04-12 |
교와 핫꼬 기린 가부시키가이샤 |
3환계 화합물
|
WO2008105326A1
(ja)
*
|
2007-02-28 |
2008-09-04 |
Ohara Chemical Industries, Ltd. |
2-イミノ-4-チアゾリジノン誘導体及び2,4-チアゾリジンジオン誘導体の製造方法
|
CL2008000684A1
(es)
|
2007-03-09 |
2008-08-01 |
Indigene Pharmaceuticals Inc |
Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
|
US8093236B2
(en)
*
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
AU2008232937B2
(en)
|
2007-03-30 |
2012-09-27 |
Ambrx, Inc. |
Modified FGF-21 polypeptides and their uses
|
US20080249156A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent and glitazones
|
US20160331729A9
(en)
*
|
2007-04-11 |
2016-11-17 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
US11241420B2
(en)
|
2007-04-11 |
2022-02-08 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
MX356965B
(es)
|
2007-04-11 |
2018-06-21 |
Omeros Corp |
Composiciones y metodos para profilaxis y tratamiento de adicciones.
|
US8034782B2
(en)
|
2008-07-16 |
2011-10-11 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
CA2690004C
(en)
|
2007-06-04 |
2018-01-23 |
Ben-Gurion University Of The Negev Research And Development Authority |
Tri-aryl compounds and compositions comprising the same
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8168416B2
(en)
|
2007-07-26 |
2012-05-01 |
Amgen Inc. |
Modified lecithin-cholesterol acyltransferase enzymes
|
EP3542801A1
(en)
*
|
2007-08-17 |
2019-09-25 |
Boehringer Ingelheim International GmbH |
Purin derivatives for use in the treatment of fap-related diseases
|
US7960376B2
(en)
*
|
2007-09-14 |
2011-06-14 |
Cara Therapeutics, Inc. |
Benzo-fused heterocycles
|
US8304441B2
(en)
|
2007-09-14 |
2012-11-06 |
Metabolic Solutions Development Company, Llc |
Thiazolidinedione analogues for the treatment of metabolic diseases
|
ES2398313T3
(es)
|
2007-09-14 |
2013-03-15 |
Metabolic Solutions Development Company Llc |
5-(4-(2-(3-metoxifenil)-2-oxoetoxi)bencil)tiazolidin-2,4-diona para uso en el tratamiento de la diabetes
|
US8722710B2
(en)
|
2007-09-26 |
2014-05-13 |
Deuterx, Llc |
Deuterium-enriched pioglitazone
|
US20090118514A1
(en)
*
|
2007-11-06 |
2009-05-07 |
Raghupathi Reddy Anumula |
Processes for preparing pioglitazone and its pharmaceutically acceptable salts
|
JP5334422B2
(ja)
*
|
2008-02-13 |
2013-11-06 |
株式会社トクヤマ |
5−{4−[2−(5−エチル−2−ピリジル)エトキシ]ベンジル}−2−イミノ−4−チアゾリジノンの製造方法
|
JP5197063B2
(ja)
*
|
2008-02-21 |
2013-05-15 |
株式会社トクヤマ |
2−ブロモ−3−{4−[2−(5−エチル−2−ピリジル)エトキシ]フェニル}プロピオン酸メチルの製造方法
|
AR071175A1
(es)
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
US20110046382A1
(en)
*
|
2008-04-28 |
2011-02-24 |
Erregierre S.P.A. |
Process for the preparation of 4-[2-(5-ethyl-2-pyridyl)ethoxy]nitrobenzene and pioglitazone
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
JP2011522828A
(ja)
|
2008-06-04 |
2011-08-04 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
|
US8486980B2
(en)
|
2008-08-06 |
2013-07-16 |
Kyowa Hakko Kirin Co., Ltd. |
Tricyclic compound
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
US8846315B2
(en)
|
2008-08-12 |
2014-09-30 |
Zinfandel Pharmaceuticals, Inc. |
Disease risk factors and methods of use
|
ME01898B
(me)
|
2008-08-12 |
2014-12-20 |
Zinfandel Pharmaceuticals Inc |
Metoda za identifikaciju faktora rizika od alchajmerove bolesti
|
PE20110297A1
(es)
*
|
2008-08-15 |
2011-05-26 |
Boehringer Ingelheim Int |
Inhibidores de dpp-4 para la cicatrizacion de heridas
|
CN102112444A
(zh)
*
|
2008-09-02 |
2011-06-29 |
株式会社德山 |
脱溴化氢化抑制剂
|
AU2009290911A1
(en)
|
2008-09-10 |
2010-03-18 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
WO2010041538A1
(ja)
*
|
2008-10-10 |
2010-04-15 |
株式会社トクヤマ |
カルボニルオキシ化合物の製造方法
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
JP5473303B2
(ja)
*
|
2008-12-01 |
2014-04-16 |
株式会社トクヤマ |
2−ブロモ−3−{4−[2−(5−エチル−2−ピリジル)エトキシ]フェニル}プロピオン酸メチルの製造方法
|
US20100144140A1
(en)
*
|
2008-12-10 |
2010-06-10 |
Novellus Systems, Inc. |
Methods for depositing tungsten films having low resistivity for gapfill applications
|
US8865729B2
(en)
|
2008-12-23 |
2014-10-21 |
Boehringer Ingelheim International Gmbh |
Salt forms of a xanthine compound
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
JP5511690B2
(ja)
*
|
2009-01-20 |
2014-06-04 |
株式会社トクヤマ |
2−ブロモ−3−{4−[2−(5−エチル−2−ピリジル)エトキシ]フェニル}プロピオン酸メチルの脱臭化水素化を抑制する方法
|
JP2010208957A
(ja)
*
|
2009-03-06 |
2010-09-24 |
Tokuyama Corp |
結晶構造を有する5−{4−[2−(5−エチル−2−ピリジル)エトキシ]ベンジル}−2−イミノ−4−チアゾリジノン及びその製造方法
|
BRPI1009141A2
(pt)
|
2009-03-11 |
2016-03-08 |
Omeros Corp |
composições e métodos para profilaxia e tratamento de vícios
|
NZ597108A
(en)
|
2009-06-25 |
2014-04-30 |
Alkermes Pharma Ireland Ltd |
Prodrugs of nh-acidic compounds
|
NZ597107A
(en)
|
2009-06-25 |
2013-12-20 |
Alkermes Pharma Ireland Ltd |
Heterocyclic compounds for the treatment of neurological and psychological disorders
|
US20110065756A1
(en)
*
|
2009-09-17 |
2011-03-17 |
De Taeye Bart M |
Methods and compositions for treatment of obesity-related diseases
|
BR112012011237A2
(pt)
|
2009-11-13 |
2019-09-24 |
Univ Tokyo |
agente terapêutico e profilático para diabetes
|
AU2010323068B2
(en)
|
2009-11-27 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
|
MX2012006725A
(es)
*
|
2009-12-15 |
2012-06-28 |
Metabolic Solutions Dev Co Llc |
Sales de tiazolidinadiona reductoras de receptores activados por proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas.
|
CA2787685A1
(en)
|
2010-01-22 |
2011-07-28 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
|
WO2011120923A1
(en)
|
2010-03-30 |
2011-10-06 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
EA033415B1
(ru)
|
2010-05-05 |
2019-10-31 |
Boehringer Ingelheim Int |
Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2
|
BR112012032579B1
(pt)
|
2010-06-24 |
2021-05-11 |
Boehringer Ingelheim International Gmbh |
uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração
|
EP2611434A1
(en)
|
2010-09-01 |
2013-07-10 |
Lupin Limited |
Pharmaceutical composition comprising metformin and pioglitazone
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
GEP201706786B
(en)
|
2011-01-10 |
2017-12-11 |
Takeda Pharmaceuticals Co |
Methods and drug products for treating alzheimer's disease
|
WO2012153312A1
(en)
|
2011-05-11 |
2012-11-15 |
Ranbaxy Laboratories Limited |
Process for the purification of pioglitazone
|
NZ618698A
(en)
|
2011-07-15 |
2015-08-28 |
Boehringer Ingelheim Int |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
KR20140051998A
(ko)
|
2011-08-03 |
2014-05-02 |
교와 핫꼬 기린 가부시키가이샤 |
디벤조옥세핀 유도체
|
WO2013068486A1
(en)
|
2011-11-08 |
2013-05-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of male infertility
|
AU2012347540A1
(en)
|
2011-12-08 |
2014-06-26 |
Amgen Inc. |
Agonistic human LCAT antigen binding proteins and their use in therapy
|
WO2013088255A1
(en)
|
2011-12-15 |
2013-06-20 |
Alkermes Pharma Ireland Limited |
Prodrugs of secondary amine compounds
|
US20130158077A1
(en)
|
2011-12-19 |
2013-06-20 |
Ares Trading S.A. |
Pharmaceutical compositions
|
US9504679B2
(en)
|
2011-12-19 |
2016-11-29 |
Bjoern Colin Kahrs |
Pharmaceutical compositions comprising glitazones and Nrf2 activators
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
EP2638898A1
(en)
|
2012-03-16 |
2013-09-18 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Metformin and Pioglitazone Formulation with Different Release Profiles
|
JP6224084B2
(ja)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
JP6453224B2
(ja)
|
2012-11-05 |
2019-01-16 |
コミッサリア ア レネルジ アトミック エ オー エネルジス アルテルナティヴスCommissariat A L‘Energie Atomique Et Aux Energies Alternatives |
インビボで血液がんの幹細胞を排除するため、および血液がんの再発を防ぐための、チロシンキナーゼ阻害剤のような抗がん剤と、好ましくはチアゾリジンジオンであるstat5アンタゴニストとの組み合わせ
|
CA2941562C
(en)
|
2013-03-14 |
2021-09-21 |
Deuterx, Llc |
Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
WO2014151200A2
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
US20140275138A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Cba Pharma, Inc. |
Method and products for treating diabetes
|
AU2014274812B2
(en)
|
2013-06-05 |
2018-09-27 |
Bausch Health Ireland Limited |
Ultra-pure agonists of guanylate cyclase C, method of making and using same
|
US9815777B2
(en)
|
2013-09-22 |
2017-11-14 |
Jiva Pharma, Inc. |
Metformin salts to treat Type2 diabetes
|
WO2015054500A2
(en)
|
2013-10-09 |
2015-04-16 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
|
AU2014347668A1
(en)
|
2013-11-05 |
2016-05-19 |
Ben-Gurion University Of The Negev Research And Development Authority |
Compounds for the treatment of diabetes and disease complications arising from same
|
EP3094328B1
(en)
|
2014-01-15 |
2020-08-19 |
Poxel SA |
Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
|
WO2015128453A1
(en)
|
2014-02-28 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Medical use of a dpp-4 inhibitor
|
KR101606547B1
(ko)
*
|
2014-06-02 |
2016-03-28 |
김동연 |
공항 탑승객 위치조회시스템
|
JP6702962B2
(ja)
|
2014-10-24 |
2020-06-03 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
改変fgf−21ポリペプチドおよびその使用
|
US10034868B2
(en)
|
2014-11-04 |
2018-07-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
|
EP3025707A1
(en)
|
2014-11-27 |
2016-06-01 |
Arven Ilac Sanayi Ve Ticaret A.S. |
A multilayer tablet comprising metformin and pioglitazone
|
CN115105601A
(zh)
|
2016-06-08 |
2022-09-27 |
投资支持有限公司 |
用于治疗癌症的药物组合
|
MX2018015089A
(es)
|
2016-06-10 |
2019-05-13 |
Boehringer Ingelheim Int |
Combinacion de linagliptina y metformina.
|
CN109562105A
(zh)
|
2016-08-17 |
2019-04-02 |
企业支持有限责任公司 |
预防或治疗听力损失的方法
|
TR201620309A2
(tr)
|
2016-12-30 |
2018-07-23 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇
|
UA127245C2
(uk)
|
2017-04-04 |
2023-06-21 |
Кінарус Аг |
Способи запобігання або лікування офтальмологічних захворювань
|
WO2019154895A1
(en)
|
2018-02-08 |
2019-08-15 |
Strekin Ag |
Gel formulation for preventing or treating hearing loss
|
WO2019154893A1
(en)
|
2018-02-08 |
2019-08-15 |
Strekin Ag |
Oral extended release pharmaceutical compositions for preventing or treating hearing loss
|
US11273158B2
(en)
|
2018-03-05 |
2022-03-15 |
Alkermes Pharma Ireland Limited |
Aripiprazole dosing strategy
|
AU2019300135A1
(en)
|
2018-07-13 |
2021-01-28 |
Kinarus Ag |
Combinations of PPAR agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
|
CN111875598B
(zh)
*
|
2020-05-23 |
2023-10-10 |
白银京宇新药业有限公司 |
一种吡格亚胺的制备方法
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
US11767317B1
(en)
|
2020-06-30 |
2023-09-26 |
Poxel Sa |
Methods of synthesizing enantiopure deuterium-enriched pioglitazone
|
EP4196120A1
(en)
|
2020-08-11 |
2023-06-21 |
Kinarus AG |
Methods of preventing or treating covid-19 and related viral diseases or disorders
|
CN115175705A
(zh)
|
2020-09-30 |
2022-10-11 |
映恩生物制药(苏州)有限公司 |
一种抗肿瘤化合物及其制备方法和应用
|
EP4385502A1
(en)
|
2022-12-15 |
2024-06-19 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A pharmaceutical formulation comprising metformin, pioglitazone and a sglt-2 inhibitor
|
EP4385501A1
(en)
|
2022-12-15 |
2024-06-19 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A pharmaceutical formulation comprising linagliptin, pioglitazone and a sglt-2 inhibitor
|